# A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen

> **NCT01107756** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 403 (actual)

## Conditions studied

- Neoplasms (no Otherwise Specified)

## Interventions

- **DRUG:** LENOGRASTIM (GRANOGYTE 34)

## Key facts

- **NCT ID:** NCT01107756
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 403 (ACTUAL)
- **Last updated:** 2012-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01107756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01107756, "A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01107756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*